GW&K Investment Management LLC Lowers Position in Globus Medical, Inc. $GMED

GW&K Investment Management LLC trimmed its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 14.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,516,345 shares of the medical device company’s stock after selling 261,086 shares during the quarter. Globus Medical comprises about 1.1% of GW&K Investment Management LLC’s investment portfolio, making the stock its 7th largest holding. GW&K Investment Management LLC’s holdings in Globus Medical were worth $132,392,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. SBI Securities Co. Ltd. increased its position in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the period. Advisory Services Network LLC bought a new position in Globus Medical during the third quarter worth about $26,000. EverSource Wealth Advisors LLC increased its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the period. Larson Financial Group LLC increased its position in Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after acquiring an additional 242 shares during the period. Finally, Parallel Advisors LLC increased its position in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the period. 95.16% of the stock is owned by institutional investors.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 18.38% of the company’s stock.

Globus Medical Stock Up 5.5%

Shares of Globus Medical stock opened at $82.60 on Wednesday. The company has a market capitalization of $11.21 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 1.61 and a beta of 0.95. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm’s 50-day moving average price is $86.08 and its two-hundred day moving average price is $88.20.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

GMED has been the topic of a number of recent research reports. Needham & Company LLC raised their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Barclays increased their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Piper Sandler reiterated an “overweight” rating on shares of Globus Medical in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.